Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyotrophic lateral sclerosis
Pharma
Amylyx to pull failed ALS drug from market, cut 70% of staff
Amylyx is pulling the ALS drug Relyvrio from the U.S. and Canadian markets after a confirmatory trial failure.
Angus Liu
Apr 4, 2024 10:06am
AZ-Daiichi, Padcev, AbbVie—Fierce Pharma Asia
Sep 29, 2023 10:45am
Amylyx's ALS drug Relyvrio continues to shine
Aug 11, 2023 11:32am
Apellis scraps pegcetacoplan development in ALS after trial flop
May 25, 2023 10:37am
FDA awards Biogen's ALS drug Qalsody an accelerated approval
Apr 25, 2023 2:28pm
Apellis hits setback in a trial of pegcetacoplan in ALS
Apr 24, 2023 11:29am